2020
DOI: 10.1016/j.clml.2020.03.003
|View full text |Cite
|
Sign up to set email alerts
|

Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
12
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 11 publications
(15 citation statements)
references
References 29 publications
3
12
0
Order By: Relevance
“…Several prognostic indices have been developed for CLL which are specific to treatment settings and therapeutic classes, but do not include a measure of comorbidity. [24][25][26][27] While the CLL-CI does add prognostic information to the CLL-IPI for all therapies currently evaluated, assessment of the influence of comorbidities alongside other prognostic scales is needed. While prognostic factors should remain key for treatment decisions, clinical trial data from pivotal phase 3 trials with novel targeted agents versus chemoimmunotherapy should be reanalyzed with addition of CLL-CI to assess the optimal treatment for patients according to CLL-CI.…”
Section: Resultsmentioning
confidence: 99%
“…Several prognostic indices have been developed for CLL which are specific to treatment settings and therapeutic classes, but do not include a measure of comorbidity. [24][25][26][27] While the CLL-CI does add prognostic information to the CLL-IPI for all therapies currently evaluated, assessment of the influence of comorbidities alongside other prognostic scales is needed. While prognostic factors should remain key for treatment decisions, clinical trial data from pivotal phase 3 trials with novel targeted agents versus chemoimmunotherapy should be reanalyzed with addition of CLL-CI to assess the optimal treatment for patients according to CLL-CI.…”
Section: Resultsmentioning
confidence: 99%
“…42 In this comparative analysis, IPS-E emerged as the score which predicted TTFT most accurately. 42 Of note, IPS-E established that in early, asymptomatic patients, TP53 mutation is not an independent predictor of TTFT. This observation reinforces previous data that TP53 aberrancy in patients with early-stage asymptomatic disease should not be treated based on TP53 status alone.…”
Section: The Utility Of Prognosticating Patients With Early Cllmentioning
confidence: 88%
“…This observation reinforces previous data that TP53 aberrancy in patients with early-stage asymptomatic disease should not be treated based on TP53 status alone. 42,43 Finally, if early intervention with novel agents is ultimately shown to have a survival benefit in asymptomatic CLL in the future, IPS-E could then be a useful tool to select patients with a higher risk of disease progression who could benefit from earlier treatment.…”
Section: The Utility Of Prognosticating Patients With Early Cllmentioning
confidence: 99%
“…Different prognostic models have been proposed to assess the TTFT for patients with early-stage CLL; however, none has been universally established in routine clinical practice [4,5,13,14,27-30], five different prognostic indexes were compared in a cohort of patients with Binet A CLL from different institutions [31]. None of the scores was able to predict with absolute precision the evolution of early CLL patients.…”
Section: Prognostic Models In Early Cllmentioning
confidence: 99%